Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual PET AV133 in Prodromal PD
NCT07809438Phase 2Recruiting
- Sponsor
- The Michael J. Fox Foundation for Parkinson's Research
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Florbenazine F-18 in Parkinson's disease (PD), sponsored by The Michael J. Fox Foundation for Parkinson's Research. Primary endpoint: Comparison of tracer uptake between two camera using Standardized Uptake Value ratio at 24 months. Started Sep 2025; status: recruiting.
02
Drugs
Florbenazine F-18
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07809438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809438.